Gadolinium-induced fibrosis testing by protein targeting assay and superparamagnetic iron oxide nanoparticle-based magnetic resonance microscopy of skin and kidneys

Interventional Medicine and Applied Science

Volumn 4, Issue 3, 2012, Pages 139-161

  Sharma, Rakesh ^a,b,c  

^a FLORIDA STATE UNIVERSITY   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

^c AMITY UNIVERSITY   (India)

Author keywords

21 Tesla MR microscopy; 500 MHz NMR; gadolinium; kidney; MRI; nephrogenic systemic fibrosis; skin; spectroscopy

Indexed keywords

EID: 84866937532     PISSN: 20611617     EISSN: 20615094     Source Type: Journal    
DOI: 10.1556/IMAS.4.2012.3.4     Document Type: Article

References (58)

1. Sieber MA, Hubertus P, Walter J, Haider W, Frenzel T, Weinmann HJ: A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium based contrast media. Invest Radiol 43, 65-75 (2008)
2. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R: Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure -role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2, 258-263 (2007)
3. Grobner T: Gadolinium -a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21, 1104-1108 (2006)
4. Piera-Velazquez S, Louneva N, Fertala J, Wermuth PJ, Galdo FD, Jimenez SA: Persistent activation of dermal fibroblasts from pateinets with gadolinium associated nephrogenic systemic fibrosis. Ann Rheum Dis 69, 2017-2023 (2010)
5. Becker S, Walter S, Witzke O, Wilde B, Hillen U, Napieralski D, Kreuter A, Altmeyer P, Scieren G, Dual A, Rump LC, Kribben A: The German registry for nephrogenic systemic fibrosis: findings from 23 patients. Clin Nephrol 73(6), 426-430 (2010)
6. Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R: Nephrogenic systemic fibrosis: pathogenesis, diagnosis and therapy. J Am Coll Cardiol 53, 1621-1628 (2009)
7. Martin DR, Krishnamoorthy SK, Kalb B, Salman KN, Sharma P, Carew JD, Martin PA, Chapman AB, Ray GL, Larsen CP, Pearson TC: Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 31(2), 440-446 (2010)
8. Boyd AS, Zic JA, Abraham JL: Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56(1), 27-30 (2007)
9. Marckmann P, Skov L, Rossen K, et al.: Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrastenhanced magnetic resonance imaging. J Am Soc Nephrol 17, 2359-2362 (2006)
10. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA: Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 188(2), 586-592 (2007)
11. Sadowshi EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A: Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiol 243, 143-157 (2007).
12. Deo A, Fogel M, Cowper SE: Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2(2), 264-267 (2007)
13. Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE: Nephrogenic Systemic Fibrosis: A review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 42(2), 139-145 (2007)
14. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56, 21-26 (2007)
15. Lim YL, Lee HY, Low SC, Chan LP, Goh NS, Pang SM: Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature. Clin Exp Dermatol 32(4), 353-358 (2007)
16. Nikken JJ, Krestin, GP: MRI of kidney-state of art. Eur Radiol 17, 2780-2793 (2007)
17. Sharma R: Gadolinium toxicity: epidermis thickness measurement by magnetic resonance imaging at 500 MHz. Skin Res Tech 16(3), 339-353 (2010)
18. Caravan P: Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. Acc Chem Res 42(7), 851-862 (2009)
19. Caravan P, Das B, Dumas S, Epstein FH, Helm PA, Jacques V, Koerner S, et al.: Collagen targeted MRI contrast agent for molecular imaging of fibrosis. Angew Chem Int Ed 46, 8171-8173 (2007)
20. Caravan P: Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 35, 512-523 (2006)
21. Caravan P, Farrar CT, Frullano L, Uppal R: Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium and manganese based T1 contrast agents. Contrast Media Mol Imaging 4, 89-100 (2009)
22. Jimenez SA, Artlett CM, Sandorfi N, et al.: Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50, 2660-2666 (2004)
23. Matsuoka T, Aiyama S, Kikuchi KI, Koike K: Uptake of cationized ferritin by the epithelium of the main excretory duct of the rat submandibular gland. Anat Rec 258, 10-113 (2000)
24. Geninatti CS, Barge A, Battistini E, Cabella C, Coluccia S, Longo D, Mainero V, Tarone G, Aime S: Magnetic resonance imaging visualization of targeted cells by the internalization of supramolecular adducts formed between avidin and biotinylated Gd3+ chelates. J Inorg Chem 10, 78-86 (2005)
25. Sharma R: Microimaging of hairless rat skin by magnetic resonance at 900 MHz. Magn Reson Imaging 27(2), 240-255 (2009)
26. Sharma R (2011): Gadolinium induced fibrosis testing by protein targeting assay and nanoparticles: magnetic resonance microimaging of skin and kidneys. In: Methods in Molecular Biology, ed John Walker, Humana Press, USA
27. Bennett KM, Zhou H, Sumner JP, Dodd SJ, Bouraoud N, Doi K, Star RA, Koretsky AP: MRI of the basement membrane using charged nanoparticles as contrast agents. Magn Reson Med 60, 564-574 (2008)
28. Brooks RA, Goldfarb RB, Bulte JWM, Aisen P: Relaxometry and magnetometry of ferritin. Magn Reson Med 40, 227-235 (1998)
29. Kim EH, Ahn Y, Lee HS: Biomedical applications of superparamagnetic iron oxide nanoparticles encapsulated within chitosan. J Alloy Comp 434-435, 633-636 (2007)
30. Bertram JF: Analyzing renal glomeruli with the new stereology. Int Rev Cytol 161, 111-172 (1995)
31. Kucher C, Xu X, Oasha T, et al.: Histopathologic comparison of naphrogenic fibrosing dermatopathy and scleromyxedema. J Cutan Pathol 32, 484-490 (2005)
32. Serkova N, Fuller TF, Klawitter J, Freise CE, Niemann CU: 1HNMR based metabolic signatures of mild and severe ischemia/ reperfusion injury in rat kidney transplants. Kidney International 67, 1142-1151 (2005)
33. Ortonne N, Lipsker D, Chantrel F, et al.: Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermatol 150, 1050-1052 (2004)
34. Knesplova L, Krestin GP: Magnetic resonance in the assessment of renal function. Eur Radiol 8, 201-211 (1998)
35. Nirendorf ER, Grist TM, Lee FT Jr., Bazy PC, Santyr GE: Rapid in vivo measurement of single kidney extraction fraction and glomerular filtration rate with MR imaging. Radiol 206, 791-798 (1998)
36. Huang AJ, Lee VS, Rusinek H: Functional renal MR imaging. Magn Reson Imaging Clin N Am 12, 469-486 (2004)
37. Chalifour RJ, McLaughlin RW, Lavoie L, Morissette C, Tremblay N, BoulüeM, Sarazin P, Ste D, Lacombe D, Tremblay P, Gervais F: Stereoselective interactions of peptide inhibitors with the betaamyloid peptide. J Biol Chem 278(37), 34874-34881 (2003)
38. Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, et al.: Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 50(2), 293-302 (2003)
39. Lowe MP: Activated MR contrast agents. Curr Pharm Biotechnol 5(6), 519-528 (2004)
40. Bridot JL, Faure AC, Laurent S, Riviere C, Billotey C, Hiba B, Janier M, Josserand V, et al.: Hybrid gadolinium oxide nanoparticles: multicontrast agents for in vivo imaging. J Am Chem Soc 129, 5076-5084 (2007)
41. Kalman FK, Woods M, Caravan P, Jurek P, Spiller M, Tircso G, Kiraly R, Brucher E, Sherry AD: Potentiometric and relaxometric properties of a gadolinium based MRI contrast agent for sensing tissue pH. Inorg Chem 46(13), 5260-5270 (2007)
42. Nivorozhkin AL, Kolodziej AF, Caravan P, Greenfield MT, Lauffer RB, McMurry TJ: Enzyme activated Gd3+ magnetic resonance imaging contrast agents with a prominent receptorinduced magnetization enhancement. Angew Chem Int Ed 40(15), 2903-2906 (2001)
43. Fukuda Y, Ohashi I, Hanafusa K, et al.: Anisotropic diffusion in kidney: apparent diffusion coefficient measurement for clinical use. JMRI 11, 156-160 (2000)
44. Chan JHM, Tsui EYK, Luk SH, et al.: MR diffusion weighted imaging of kidney: differentiation between hydronephrosis and pyonephrosis. Clin Imaging 25, 110-113 (2001)
45. Bulte JW, Douglas T, Mann S, Frankel RB, Moskowitz BM, Brooks RA, et al.: Magnetoferritin: characterization of novel superparamagnetic MR contrast agent. JMRI 4, 497-505 (1994)
46. Geninatti Chric S, Bussolati B, Tei L, Grange C, Esposito G, Lanzardo S, Camussi G, et al.: Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. Cancer Res 66, 9196-9201 (2006)
47. Baumann D, Rudin M: Quantitative assessment of rat kidney function by measuring the clearance of the contrast agent Gd(DOTA) using dynamic MRI. MRI 18, 587-595 (2000)
48. Kobayashi H, Kawamoto S, Yasuda H, Hu X, Knopp MV, Brechbiel MW, Choyke OL, et al.: Polyamine dendrimer based MRI contrast agents for functional kidney imaging to diagnose acute renal failure. J Magn Reson Imaging 20, 512-518 (2004)
49. Sharma R: Nanoparticles that facilitate imaging of biological tissue and methods of forming the same. US Patent Issue No. 0220434 (2009)
50. Yang D, Ye Q, Williams M, Sun Y, Hu Tom C-C, William DS, Moura JMF, Ho C: USPIO enhanced dynamic MRI: evaluation of normal and transplanted rat kidneys. Magn Reson Med. 46, 1152-1163 (2001)
51. Buckley DL, Shurrab AE, Cheung CM, Jones AP, Mamtora H, Kalra PA: Measurement of single kidney function using dynamic contrast-enhanced MRI: comparison of two models in human subjects. J Magn Reson Imaging 24, 1117-1123 (2006)
52. Notle-Ernsting CC, Tacke J, Adam GB, et al.: Diuretic enhanced gadolinium excretory MR urography: comparison of conventional gradient-echo sequences and echoplanar imaging. Eur Radiol 11, 18-27 (2001)
53. Ritt M, Janka R, Schneider MP, Martirosian P, Hornegger J, Bautz W, Uder MR, Schmieder E: Measurement of kidney perfusion by magnetic resonance imaging: comparison of MRI with arterial spin labeling to para-aminohippuric acid plasma clearance in male subjects with metabolic syndrome. Nephrology Dialysis Transplantation 25(4), 1126-1133 (2010)
54. Parsons AC, Gil Y, Sheehan DJ, Sangüeza OP, Greenberg CS, Sane DC: Transglutaminases: The Missing Link in Nephrogenic Systemic Fibrosis. Am J Dermatopathol 29(5), 433-526 (2007)
55. Ersoy H, Rybicki FJ: Biochemical safety profiles of gadoliniumbased extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 26, 1190-1197 (2007)
56. Macqueen DB: Gadolinium exchanged carboxylate alumoxanes as MRI contrast agents. WO 113556 (2006) and PCT/US 014291 (2006)
57. Zhang JL, Sigmund EE, Chandarana H, Rusinek H, Chen Q, Vivier H, Taouli B, Lee VS: Variability of renal apparent diffusion coefficients: Limitations of monoexponential model for diffusion quantification. Radiol 254(3), 783-792 (2010)
58. Artunc F, Yildiz S, Rossi C, Boss A, Dittmann, H, Schlemmer HP, Risler T, Heyne N: Simultaneous evaluation of renal morphology and function in live kidney donors using dynamic magnetic resonance imaging. Nephrol Dial Transplant 25(6), 1986-1991 (2010)